[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scar\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scar":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,71,93,122,148,175,203,229,254,286,314,338,369],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100470611","impact-of-suture-type-on-pigment-disturbances-in-patients-of-skin-of-color-100470611",false,"NCT05408117","Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color","Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color: A Prospective, Randomized Split-wound Study","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Undergoing dermatologic surgery with planned standard elliptical excision with wound length of 3 cm or greater. Benign and malignant lesions will be included, including those that have undergone Mohs micrographic surgery prior to standard linear closure. All body sites will be included.\n3. Able to give informed consent\n4. Able to return for 3 month follow up\n5. New Immigration Scale (NIS) skin color 4 or greater - The NIS is an 11 point scale, ranging from zero to 10, with zero representing albinism and 10 representing the darkest possible skin.\n\nExclusion Criteria:\n\n1. High-tension closures not amenable to 5-0 simple running epidermal sutures\n2. Known allergy to suture material\n3. Pregnant","ALL","18 Years",{"count":19,"type":20},34,"ESTIMATED","INTERVENTIONAL",[23],"NA","The present study assesses if dissolvable (fast gut) or non-dissolvable (polypropylene) epidermal sutures produce better cosmetic results in terms of dyspigmentation and scarring in patients of skin of color. Through a split-wound study design, patients undergoing standard elliptical excisions at least 3 cm in length will receive each suture type. Measurements of dyspigmentation and scarring will be made at 7 days (for the head and neck), 10 days (for the trunk and extremities), and 3 months for all locations.",[26],"Scar",[28,29,30,31,32],"skin of color","split-wound","polypropylene","fast gut","pigmentary disturbance","RECRUITING","2026-06-02",{"date":36,"type":37},"2026-06-04","ACTUAL",{"date":39,"type":37},"2022-10-01",{"date":41,"type":20},"2027-10-01",{"name":43,"class":44},"Melissa Pugliano-Mauro","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100529254","microneedling-vs-dermabrasion-for-early-facial-scar-resurfacing-100529254","NCT06171386","Microneedling vs Dermabrasion for Early Facial Scar Resurfacing","Inclusion Criteria:\n\n* Volunteer adult patients will be identified by visiting the Facial Plastics and Reconstructive Surgery Clinic at Atrium Health Wake Forest Baptist.\n* Patients will be 18 years old+ and have a vertical surgical scar in the superior 1\u002F3 of the face (trichion to glabella).\n* Patients will enroll in the clinic research registry and indicate an interest in being involved in the study.\n\nExclusion Criteria:\n\n* Patients who rate Types 4-6 on the Fitzpatrick scale will be excluded due to risk of poor outcome from dermabrasion.\n* There are no other planned exclusion criteria. Patients will not be excluded on the basis of gender, race\u002Fethnicity, or age, provided that they meet the described inclusion criteria.",{"count":53,"type":20},30,[23],"This study aims to determine whether microneedling or dermabrasion in the early post-operative period is superior in improving the appearance of surgical scars on the face.",[26],[58,59,60],"Dermabrasion","Microneedling","Surgical scars","2026-05-05",{"date":63,"type":37},"2026-05-07",{"date":65,"type":37},"2024-04-01",{"date":67,"type":20},"2027-04",{"name":69,"class":44},"Wake Forest University Health Sciences",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":70},"100637371","phase-2-a-phase-ii-study-of-9mw3811-in-patients-with-pathological-scar-100637371","NCT07576608","A Phase II Study of 9MW3811 in Patients With Pathological Scar","A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Properties, and Preliminary Efficacy of 9MW3811 in Patients With Pathological Scar","Inclusion Criteria:\n\n* Age ≥18 years\n* Pathological scar with no spontaneous regression over the prior 6 months\n* At least one scar with modified Vancouver Scar Scale (mVSS) score ≥9\n* Willing to use effective contraception for 6 months after last dose (if of childbearing potential)\n* Provide written informed consent\n\nExclusion Criteria:\n\n* Contracture scar causing deformity\n* All eligible scars either \\>10 cm in length and \\>5 cm in width, or located exclusively on sun-exposed areas (head, face, hands)\n* Evidence of scar infection or active systemic infection requiring treatment\n* Use of anti-scar medications (e.g., corticosteroids, immunosuppressants) or anti-scar procedures (surgery, laser, radiation, etc.) within 4 weeks prior to first dose\n* Prior treatment with IL-11 cytokine or IL-6 family targeted therapy (e.g., tocilizumab) within specified washout periods\n* Participation in another interventional study within 28 days\n* Positive serology for HBV, HCV, HIV, or syphilis with clinical significance\n* History of severe allergy or known hypersensitivity to study drug components\n* Clinically significant laboratory abnormalities (eGFR \\\u003C90 mL\u002Fmin\u002F1.73m², PLT \\\u003C100×10⁹\u002FL, QTc \\>450\u002F470 ms, bilirubin \\>1.5×ULN, AST\u002FALT \\>1.5×ULN)\n* Alcohol or drug abuse within 1 year\n* Pregnancy, breastfeeding, or unwillingness to use contraception\n* Any other condition that, in the investigator's judgment, would compromise subject safety or study compliance",{"count":53,"type":20},[80],"PHASE2","This is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of 9MW3811 in patients with pathological scar.",[26],"2026-04-30",{"date":85,"type":37},"2026-05-08",{"date":87,"type":37},"2025-12-29",{"date":89,"type":20},"2026-12",{"name":91,"class":92},"Mabwell (Shanghai) Bioscience Co., Ltd.","INDUSTRY",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":70},"100541913","pre-marketing-trial-to-assess-safety-and-efficacy-of-volumizing-filler-based-on-hyaluronic-acid-and-recombinant-collagen-100541913","NCT06336044","Pre-marketing Trial to Assess Safety and Efficacy of 'Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen'","\"Clinical and Instrumental Evaluation of the Safety and Bio-revitalizing Effect on the Face of the Medical Device 'Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen'\"","Inclusion Criteria:\n\n* all sexes\n* caucasic\n* 18 to 70 years\n* non smoker\n\nExclusion Criteria:\n\n* Pregnancy\n* milking\n* smoker\n* alcohol or drugs abuse\n* change of BMI during the study\n* previous facial surgery, implants, permanent treatments\n* sensitivity to the product\n* dermatological difficult frame\n* health weakness\n* treated with anticoagulants, antihistaminics, corticosteroids, antidepressants and other drugs impacting on the results","70 Years",{"count":102,"type":20},40,[23],"Study to validate the safety and efficacy of the Hyaluronic Acid +Collagen filler 40 patients will undergo through 3 visits one to asses the health and apply the filler one after 4 weeks to check the results one after 16 weeks for the final check and results validation Safety assessed with analysis of the Adverse Events",[106,26,107],"Wrinkle","Laxity; Skin",[109,110,111,112],"hyaluronic acid","Collagen","Filler","Wrinkles","2026-01-22",{"date":115,"type":37},"2026-01-26",{"date":117,"type":20},"2026-02",{"date":119,"type":20},"2026-06",{"name":121,"class":92},"Taumedika s.r.l.",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":70},"100602994","effect-of-myofascial-release-versus-deep-friction-massage-on-abdominal-recovery-and-scar-after-cesarean-section-100602994","NCT07130747","Effect of Myofascial Release Versus Deep Friction Massage on Abdominal Recovery and Scar After Cesarean Section","Inclusion Criteria:\n\n1. All postpartum women \\>6 months postnatal having a post-Cesarean-section scar.\n2. Postpartum women with a well-healed cesarean section scar resulted in chronic pain in the scar, pelvis, or abdomen.\n3. Their ages will range from 30 to 45 years.\n4. Their body mass index (BMI) is less than 30 kg\u002Fm².\n\nExclusion Criteria:\n\n1. Pregnant women or planning for pregnancy.\n2. Postpartum women with abdominal infectious diseases.\n3. Cardiovascular diseases.\n4. Previous spinal surgery.\n5. History of skeletal deformity.\n6. Participation in any other exercise training program during this study.\n7. Malignant condition\n8. History of acute infection\n9. Neurological problem\n10. Mental problem to prevent evaluation and cooperation\n11. Having uncontrolled metabolic diseases like diabetes and thyroid disease","FEMALE","30 Years","45 Years",{"count":132,"type":20},36,[23],"This study was done to compare the effect of myofascial release versus deep friction massage on abdominal recovery and scar after cesarean section.",[136,137,138,26],"Myofascial Release","Deep Friction Massage","Cesarean Section Complications","2025-08-16",{"date":141,"type":37},"2025-08-19",{"date":143,"type":37},"2025-06-01",{"date":145,"type":20},"2025-10-01",{"name":147,"class":44},"Cairo University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":155,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":159,"conditions":160,"keywords":166,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":70},"100328836","early-phase-1-zinc-oxide-versus-petrolatum-following-skin-surgery-100328836","NCT03561376","Zinc Oxide Versus Petrolatum Following Skin Surgery","Zinc Oxide Versus Petrolatum Following Skin Surgery: A Head-to-head, Prospective, Split-scar Study","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Linear closure, non-scalp site\n3. ≥ 4.5 cm in length (final incision\u002Fclosure length)\n4. End to end symmetry (surgical site is not grossly asymmetric from end to end)\n5. Grossly uninfected site\n\nExclusion Criteria:\n\n1. ≤ 18 years\n2. Visibly asymmetric linear scar\n3. Grossly infected surgical site\n4. History of allergy to topical zinc oxide",true,{"count":53,"type":20},[158],"EARLY_PHASE1","Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respective ointments to each half of scar daily for one month and maintain a log of these activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale (POSAS), a quantitative objective assessment of scar appearance. Trained observers (board-certified dermatologists) will score the observer portion of the scale. POSAS outcomes, post-operative infections, linear density of epidermal seal will be assessed at the 1 week, 4 weeks, 8 weeks, and 6 months post-operative periods and compared between the two groups. Participants will have parking validated for all visits and upon completion of all portions of the study will receive a standardized skin care gift bag containing samples for hypoallergenic skin care products (washes, moisturizers, etc.).",[161,162,163,164,26,165],"Surgical Incision","Surgery--Complications","Surgical Wound","Surgical Site Infection","Hypertrophic Scar",[26],"2025-08-12",{"date":169,"type":37},"2025-08-14",{"date":171,"type":37},"2021-09-01",{"date":173,"type":20},"2026-10-30",{"name":43,"class":44},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":188,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":70},"100576560","paraffin-wax-and-exercise-prospective-100576560","NCT06786884","Paraffin Wax and Exercise Prospective","A Pilot, Randomized Controlled Trial Evaluating the Effectiveness of Paraffin Wax On Burn Patient Function, Range of Motion and Scar","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with burn scar that crosses an upper or lower extremity joint (shoulder, elbow, wrist, hand, hip, knee, ankle)\n* Patients that have been prescribed a rehabilitation program where paraffin wax could be used as an adjunct to rehab exercise therapy\n\nExclusion Criteria:\n\n* Adults unable to provide informed consent\n* Injury etiology other than burn (ex: cutaneous trauma, cold injury, etc.)\n* Pregnant women\n* Prisoners",{"count":53,"type":20},[23],"This study is being done to test if paraffin wax can be used to improve the range of motion and function for scars across joints when used in combination with scar rehabilitation therapy sessions. For those randomized to receive it, the paraffin wax will be used alongside the participants' exercise therapy treatments. Currently, treatments that are used in addition to rehabilitation therapy for increasing range of motion across joints in the burn population are limited. By getting more information about how paraffin wax may or may not work, patients in the future that have scars may be able to be helped.",[186,26,187],"Burn","Exercise Therapy",[189,190,191,192,193],"paraffin wax","burn scar","scar","burn","range of motion","2025-06-10",{"date":196,"type":37},"2025-06-13",{"date":198,"type":37},"2025-01-06",{"date":200,"type":20},"2027-02",{"name":202,"class":44},"Medstar Health Research Institute",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":228},"100579495","the-effects-of-extracorporeal-shock-wave-therapy-in-postsurgical-scars-especially-after-abdominplasty-and-breast-reduction-100579495","NCT06825039","The Effects of Extracorporeal Shock Wave Therapy in Postsurgical Scars Especially After Abdominplasty and Breast Reduction.","The Effects of Extracorporeal Shock Wave Therapy in Different Stages of Scar Formation in Postsurgical Scars Especially After Abdominplasty and Breast Reduction.","Effect of SWT","Inclusion criteria\n\n* Eligible patients aged between 18 and 80 years\n* Dutch or English speaking\n* Patients who had undergone an abdominoplasty resulting in a dermal scar\n* Informed consent (approved by the ethics committee) will be provided before the surgical intervention Exclusion criteria\n* All type of skin diseases or dermatological problems\n* Previous surgery or ESWT intervention at the current scar site\n* Age under 18 years or above 80 years\n* Inability to provide informed consent\n* Expected problems in therapy compliance or follow up\n* Pregnancy","80 Years",{"count":213,"type":20},150,[23],"Scars can be caused by physical trauma, surgical incisions, burn injuries and even acne. Deep cutaneous injuries induce pathological scars. Other factors, such as mechanical loading, bacterial colonization are potential factors thought to underlie human hypertrophic and keloid scar formation or contractures. The effect may include functional impairment and aesthetic disadvantages.\n\nVarious non-invasive mechanical interventions of physical scar management (e.g. extracorporeal shock wave therapy or ESWT) could have a beneficial influence on wound healing and prevention of hypertrophic scars. ESWT considerably improves the appearance and symptoms of hypertrophic scars. However, the mechanism underlying the observed beneficial effects is not well understood. The objective of the first part of the study is to elucidate the mechanism underlying changes in cellular mechanosensitive pathways that are induced by ESWT. This review will introduce the histopathological effects on ESWT during wound healing and scar development.\n\nThe main objective of this study is to determine how much mechanical loading on dermal scars will lead to normal scar healing. The optimal duration, the frequency and the intensity of the applied forces in ESWT to generate a beneficiary effect during different phases of wound healing remains unclear.\n\nIn this study, biopsies from abdomionplasty postsurgical scars will be examined. Thereby it is possible to evaluate the outcomes on a cellular level through assessing the histology of human biopsies under controlled condition. In the second part, the underlying mechanism of ESWT on postsurgical scars will be explored, in different stages of wound healing. Furthermore, the investigators will investigate if changes in physical characteristics (redness, thickness and pliability) in postsurgical scars are associated with changes in reactivity of mechanosensitive pathways. This study will close the gap between the fundamental knowledge on cellular mechanotransduction and the clinical application of mechanotherapy during physical scar management (ESWT).",[26,217],"Shockwave Therapy",[219],"Skin scars, Post surgical, Underlying mechanisms, Shock wave","2025-03-03",{"date":222,"type":37},"2025-03-06",{"date":224,"type":37},"2023-12-20",{"date":200,"type":20},{"name":227,"class":44},"Universiteit Antwerpen",4,{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":21,"phases":239,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":70},"100401362","silicone-taping-for-the-improvement-of-abdominal-donor-site-scars-100401362","NCT04506255","Silicone Taping for the Improvement of Abdominal Donor Site Scars","Silicone Taping for the Improvement of Abdominal Donor Site Scars Following Autologous Breast Reconstruction; A Randomized, Prospective Controlled Trial","Inclusion Criteria:\n\n* undergoing de novo abdominoplasty procedures as part of their breast reconstruction\n\nExclusion Criteria:\n\n* patients with a history of collagen disease, connective tissue disorders, psoriasis or lupus\n* patients with scleroderma\n* patients with a history of adverse reaction to adhesives or silicone allergy\n* patients with signs of dehiscence or infection resulting in modification to the experimental or control dressings\n* patients who are unable to care for their incisions\n* patients who are current smokers\n* patients who are currently on steroids.","65 Years",{"count":238,"type":20},32,[23],"This study will look at silicone tape compared to the current no dressing standard at the investigators institution, to determine if silicone tape provides a significant improvement in post-abdominoplasty scar appearance. Silicone tape will be added to half of the abdominoplasty incision of patients undergoing abdominally-based breast reconstruction procedures two weeks after their operation. They will be followed up and assessed at specific timepoints to determine whether the silicone improves scar outcomes in these patients.",[165,26],[243,26,244,245],"Silicone","Abdominoplasty","Breast Reconstruction","2025-02-16",{"date":248,"type":37},"2025-02-18",{"date":250,"type":37},"2020-11-16",{"date":89,"type":20},{"name":253,"class":44},"Nova Scotia Health Authority",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":271,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":70},"100530774","cosmetic-outcome-of-electrocautery-scalpel-and-peak-plasmablade-for-surgical-breast-incisions-100530774","NCT06191159","Cosmetic Outcome of Electrocautery, Scalpel and PEAK PlasmaBlade for Surgical Breast Incisions","A Randomized Controlled Trial Comparing the Cosmetic Outcome of Electrocautery, Scalpel and PEAK PlasmaBlade for Surgical Breast Incisions","SCPPB","Inclusion Criteria:\n\n* Patients having a total mastectomy with or without axilla surgical staging\n\nExclusion Criteria:\n\n* Patients having immediate breast reconstruction\n* Patients with a diagnosis of inflammatory breast cancer\n* History of keloid scar formation\n* History of connective tissue disorder (scleroderma or rheumatoid arthritis with skin involvement)\n* Patients with prior incision at the planned mastectomy site.\n* Patients with known suture hypersensitivity\n* Patients with evidence of current infection",{"count":263,"type":20},186,[23],"This study will compare the cosmetic scar result from the use of scalpel, electrocautery, and pulsed electron avalanche knife (PEAK) PlasmaBlade (PPB) for the initial skin incision for total mastectomy procedures without immediate breast reconstruction.\n\nIt is hypothesized that there will be no significant difference in mastectomy scar cosmesis.\n\nThe purpose and objectives of this study are:\n\n1. To evaluate and compare the cosmetic scar result from the use of scalpel, standard electrocautery, or PEAK PlasmaBlade for initial incision for total mastectomy procedures without immediate breast reconstruction.\n2. To inform future equipment choices for breast surgery including potential elimination of scalpels and their attendant risks.",[267,268,269,270,26],"Wound Complication","Surgical Wound Infection","Post-operative Pain","Postoperative Complications",[272,273,274,275,276],"Electrocautery","PEAK PlasmaBlade","Scalpel","Mastectomy","Incision","2024-12-10",{"date":279,"type":37},"2024-12-16",{"date":281,"type":37},"2024-12-09",{"date":283,"type":20},"2025-12",{"name":285,"class":44},"University of British Columbia",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":155,"sex":16,"minAge":17,"maxAge":236,"enrollmentInfo":293,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":70},"100557050","infrared-led-lighting-application-and-wound-healing-100557050","NCT06533072","Infrared LED Lighting Application and Wound Healing","The Effect Of Infrared Led Lıght Applıcatıon On Wound Healıng, Scar And Scar Tıssue Formatıon In Patıents Havıng Laparascopıc Cholesystectomy Surgery","Inclusion Criteria:\n\n* being over 18 years and under 65 years old\n* Volunteer to participate in the study\n* Having cognitive competence\n* Absence of any chronic disease (diabetes, COPD, hypertension, etc.)\n* Not Separating the Wound\n* Tympanic body temperature; 35.7-37.5; axillary; It should be between 36.5 and 37.0\n\nExclusion Criteria:\n\n* Presence of signs and symptoms of infection at the wound site\n* Unusual bleeding at the wound site\n* Patients are given hypertensive, anticoagulant, thyroid etc. starting medications",{"count":294,"type":20},80,[23],"Laparoscopic cholecystectomy is a commonly used procedural procedure for removal of the gallbladder. Following this healing, wound healing, scar formation and scar tissue formation are critical factors in the healing process. The development of painless, noninvasive, biophysical therapeutic interventions has become the focus of current biomedical research. In recent years, it has been reported that infrared (IR) LED light applications have positive effects on tissue healing processes. This study will be conducted in a randomized controlled manner to examine the effect of postoperative IR LED application on wound healing, scarring and scar tissue formation in patients who underwent laparoscopic cholecystectomy.The research will be carried out at Erzurum City Hospital General Surgery Clinic between 15.08.2024-30.08.2025. A number sequence will be created for the 80 patients in the sample who meet the inclusion criteria for the experimental group and control group, and they will be assigned to the experimental (n = 40) and control groups (n = 40) using a computerized randomization program (https:\u002F\u002Fwww.random.org\u002Finteger-sets\u002F) patient distribution will be provided. First of all, IR LED light application; It is applied on Post-Operative Day 1 and postoperative day 2. It will be given four times in total, from a distance of 45-60 cm, for 20 minutes at 8 hour intervals. On the 15th and 30th post-operative day, the patient will be asked to come to the hospital and the wound site will be re-evaluated and the data collection form will be filled out again. The patient's pain status will be evaluated with VAS, and satisfaction with Newcastle Nursing Care Satisfaction Scale. Wound and scar tissue will be examined with the Bates Jensen wound assessment scale and the patient and observer scar assessment scale. Wound and scar sites will be re-evaluated after the 15th and 30th post-operative day. The patient's pain status will be evaluated with VAS, and satisfaction with Newcastle Nursing Care Satisfaction Scale. Wound and scar tissue will be examined with the Bates Jensen wound assessment scale and the patient and observer scar assessment scale. The wound margin will be measured with a disposable ruler. In coding and evaluating the data; SPSS 22.00 package program will be used.",[298,299,26],"Cholecystectasia","Wound Heal",[301,302,303,304],"surgical wound","Photobiomodülation","Ligh","Therapy","2024-07-29",{"date":307,"type":37},"2024-08-01",{"date":309,"type":37},"2024-06-15",{"date":311,"type":20},"2025-12-30",{"name":313,"class":44},"Ardahan University",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":155,"sex":16,"minAge":17,"maxAge":236,"enrollmentInfo":321,"targetDuration":4,"studyType":21,"phases":322,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":337},"100477773","phase-2-dose-regimen-study-of-sli-f06-in-healthy-volunteers-100477773","NCT05501327","Dose Regimen Study of SLI-F06 in Healthy Volunteers","A Randomized, Within Subject Controlled, Dose Regimen Study of SLI-F06 in Healthy Volunteers for Improvement in Scar Appearance","Inclusion Criteria:\n\n1. Healthy subjects, male or female, ages 18 to 65\n2. Subjects with a Body Mass Index (BMI) 18.5-30 and at least 40 kg\n3. Subjects with symmetrically located right and left scapular lines relative to the midline, and at least 12 cm distance between the right and left scapular lines.\n4. Be able to follow study instructions and likely to complete all required visits.\n5. Sign the Institutional Review Board (IRB)-approved informed consent form (ICF, which includes the Photographic and Video Release Form) prior to any study-related procedures being performed.\n\nExclusion Criteria:\n\n1. Female subjects who are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control methods\n2. Subjects who were previously treated with SLI-F06\n3. Subjects with evidence of hypertrophic or keloid scarring\n4. Subjects with obvious back abnormalities (e.g., severe scoliosis)\n5. Subjects with tattoos or previous scars in the study areas\n6. Subjects who are poor surgical candidates\n\n   1. Active disease that could interfere with or limit wound healing (e.g., diabetes, anemia, renal disease, hepatic disease, cardiac disease, or immune system disorders)\n   2. History of clinically significant bleeding disorder or coagulation disorders\n   3. Use of any tobacco\u002Finhaled nicotine products including vaping within 12 months.\n7. Subjects with evidence of skin infection or rash on the back\n8. Subjects with history of active or uncontrolled skin disease (e.g., psoriasis, eczema, rosacea, vitiligo, skin cancer) that could interfere with the study or interpretation of the study outcomes\n9. Subjects with a history of clinically significant allergies, especially drug hypersensitivity to lignocaine or allergy to adhesive surgical dressings\n10. Subjects with any clinically significant abnormality following review of pre-study laboratory data and full physical examination\n11. Subjects who are taking or have taken known anticoagulants:\n\n    1. Blood thinners (e.g., coumadin, rivaroxaban, apixaban) within 2 months prior to day 0\n    2. Others such as aspirin or aspirin containing products, Non-steroidal anti-inflammatory drugs (NSAIDs), vitamin E, fish oil within 14 days prior to day 0.\n12. Subjects taking systemic or topical steroids within 4 weeks of Day 0\n13. Subjects with excessive alcohol use, defined as \\>28 units of alcohol per week (1unit = 8 g alcohol, 1shot spirits, half- pint beer, or 5 oz wine)\n14. Subjects who have evidence of drug abuse\n15. Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen per medical history\n16. Subjects with a history of poor or delayed wound healing (e.g., prior wound dehiscence, chronic wound, leg ulcer)\n17. Subjects treated with an investigational drug or device within 30 days prior to day 0\n18. Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, or may significantly interfere with the subject's participation in the study",{"count":53,"type":20},[80],"Multi-center, dose-regimen, double-blind study evaluating the safety and efficacy of 4 doses of SLI-F06 compared with vehicle for improvement in scar appearance",[26,325],"Wound Healing",[26,327,325],"Scar Appearance","2023-07-24",{"date":330,"type":37},"2023-07-27",{"date":332,"type":37},"2022-07-25",{"date":334,"type":20},"2024-10-25",{"name":336,"class":92},"Scarless Laboratories, Inc.",2,{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":128,"minAge":345,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":368},"100335402","partial-breast-versus-no-irradiation-for-women-with-early-breast-cancer-100335402","NCT03646955","Partial Breast Versus no Irradiation for Women With Early Breast Cancer","The DBCG RT Natural Trial: Partial Breast Versus no Irradiation for Women >=60 Years Operated With Breast Conservation for an Early Breast Cancer: a Clinically Controlled Randomized Phase III Trial","Inclusion Criteria:\n\nFemale patient \\>=60 years\n\nPrimary tumour characteristics by conventional histopathology\n\n* unilateral and unifocal non-lobular histology grade 1-2\n* maximum microscopic size \\\u003C=20mm\n* node negative determined by sentinel node or axillary lymph node dissection\n* estrogen receptor \\>=10% positive\n* HER2 negative (by IHC and\u002For in situ hybridization)\n* resection margin \\>=2 mm for invasive carcinoma and any ductal carcinoma in situ associated with the cancer\n\nSurgical type is breast conservation\n\nPerformance status ECOG 0-2\n\nNo evidence of distant metastasis\n\nExclusion Criteria:\n\n* multifocal or multicentric invasive carcinoma or ductal carcinoma in situ\n* evidence of clinical or pathological T4 breast cancer\n* grade 3 malignancy\n* previous breast cancer or DCIS irrespective of disease-free interval\n* previous radiation therapy to the breast or thorax,\n* previous neoplasm within 5 years except carcinoma in situ of the cervix, endometrium or coli, melanoma in situ.\n* comorbidity precluding the patient from radiation therapy (e.g. cardiovascular or pulmonary disease, scleroderma, systemic lupus erythematosus).\n* mental\u002Fpsychiatric disorder which precludes the patient from understanding the randomization and the follow up.\n* documented hereditary breast cancer or with high genetic risk of breast cancer\n* life expectancy \\\u003C10 years","60 Years",{"count":347,"type":20},926,[23],"All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after breast conserving surgery for an early breast cancer. Breast cancer is heterogeneous, and selected patients have a very low gain from RT, whilst they still have risk of acute and late side effects from RT. This trial will try identify selection criteria for low risk breast cancer patients who can safely omit adjuvant RT without unacceptable high risk of local failure.",[351,352,353,354,355,356,26,357,358],"Local Neoplasm Recurrence","Distantly Metastatic Malignant Neoplasm","Death","Fibrosis Breast","Depigmentation\u002FHyperpigmentation of Skin","Telangiectasia","Pain","PROMs","2020-10-05",{"date":361,"type":37},"2020-10-06",{"date":363,"type":37},"2018-09-05",{"date":365,"type":20},"2035-09-01",{"name":367,"class":44},"Danish Breast Cancer Cooperative Group",17,{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":211,"enrollmentInfo":376,"targetDuration":4,"studyType":21,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":70},"100392374","tissue-engineered-skin-graft-repair-of-autologous-scar-dermal-scaffolds-100392374","NCT04389164","Tissue-engineered Skin Graft Repair of Autologous Scar Dermal Scaffolds","A Multicenter, Randomized, Controlled Clinical Trial of Tissue-engineered Skin Grafts With Autologous Scar Dermal Scaffolds for the Repair of Hypertrophic Scars","Inclusion Criteria:\n\nThe patient is diagnosed as hypertrophic scar and needs surgical repair; The scar size was 10cm2 to 200cm2, and the site was not limited; Patients with stable vital signs and tolerable operation indicated by routine examination; Patients in good mental state, can follow the doctor's advice, regular return; Those whom the researchers considered unsuitable for inclusion; Patients have participated in this study at any time in the past; Those whom the researchers considered unsuitable for inclusion; Patients have participated in this study at any time in the past.\n\nExclusion Criteria:\n\nThose who did not meet the inclusion criteria were found after the selected subjects; The follow-up time after inclusion was less than 2 times, and the objective efficacy could not be evaluated (but the adverse reactions could be evaluated); Subjects who violate protocol requirements.",{"count":377,"type":20},226,[23],"Hypertrophic scar is an inevitable outcome of wound repair. It affects the appearance and some scar contracture often leads to joint dysfunction.Patients have low quality of life, long treatment cycle, heavy social burden and high medical costs.Skin grafting is currently the gold standard for scar repair.However, there are often insufficient skin sources, easy to scar recurrence, lack of skin accessory organs.The application of composite skin graft can reduce the recurrence rate of scar healing and relieve the deficiency of skin source.However, its survival rate is not high, and acellular allogeneic dermal scaffolds are expensive, heavy medical burden.Therefore, how to effectively repair the wound surface after surgical excision of scar is the main problem to be solved urgently.\n\nDermal loss is the main cause of unsatisfactory scar repair and recurrence.The previous clinical study of the research group found that the application of autologous epidermal basal cells and autologous skin graft obtained in real time during the operation could effectively improve the survival rate of skin graft in the treatment of wound surface (Brit J Surg, 2015).Furthermore, it is suggested that the application of autologous scar dermal scaffolds can achieve the control of skin damage in the skin harvesting area and the orthotopic transplantation of autologous scar tissue dermal scaffolds, which can effectively reduce the economic burden of patients.Therefore, the researchers wondered whether the construction of tissue-engineered skin orthotopic transplantation with autologous epidermal basal cells and autologous scar dermal scaffold combined with autologous scar dermal scaffolds to repair the wound after scar resection could improve the survival rate of skin graft and reduce scar recurrence.To this end, we plan to carry out multi-center, prospective, randomized, controlled clinical trials, aiming at proposing more effective surgical treatment guidelines for the repair of hypertrophic scar, improving the survival rate of composite skin graft, and solving the current clinical problems of hypertrophic scar repair.",[26],"2020-05-11",{"date":383,"type":37},"2020-05-15",{"date":385,"type":37},"2019-03-01",{"date":387,"type":20},"2027-12-31",{"name":389,"class":44},"First Affiliated Hospital, Sun Yat-Sen University"]